UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinically Significant Psychotropic Drug-Drug Interactions in the Primary Care Setting

Current psychiatry reports, 2012-08, Vol.14 (4), p.376-390

2012

Volltextzugriff (PDF)

Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disorders

Neuropsychopharmacology (New York, N.Y.), 2021-03, Vol.46 (4), p.844-850

2021

Volltextzugriff (PDF)

Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease

Journal of neuroinflammation, 2017-08, Vol.14 (1), p.164-164, Article 164

2017

Volltextzugriff (PDF)

Relationships Among Subjective and Objective Measures of Adherence to Oral Antipsychotic Medications

Psychiatric services (Washington, D.C.), 2007-09, Vol.58 (9), p.1187-1192

2007

Volltextzugriff (PDF)

Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies

Human psychopharmacology, 2013-09, Vol.28 (5), p.495-505

2013

Volltextzugriff (PDF)

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients

Science translational medicine, 2016-11, Vol.8 (363), p.363ra150

2016

Volltextzugriff (PDF)

Drug-drug interactions with the use of psychotropic medications. Interview by Diane M. Sloan

CNS spectrums, 2009-08, Vol.14 (8 Suppl Q and A Forum), p.1

Ereshefsky, Larry

2009

Volltextzugriff (PDF)

Pharmacokinetics and drug interactions: update for new antipsychotics

The journal of clinical psychiatry, 1996, Vol.57 Suppl 11, p.12

Ereshefsky, L

1996

Volltextzugriff (PDF)

Diagnostic criteria for apathy in neurocognitive disorders

Alzheimer's & dementia, 2021-12, Vol.17 (12), p.1892-1904

2021

Volltextzugriff (PDF)

Quantitative EEG as a translational measure for the assessment of ATH‐1017 neurophysiological changes in mild‐to‐moderate Alzheimer’s disease

Alzheimer's & dementia, 2021-12, Vol.17 (S5), p.n/a

2021

Volltextzugriff (PDF)

AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease

Journal of Alzheimer's disease, 2017-01, Vol.55 (3), p.1039-1053

2017

Volltextzugriff (PDF)

Experimental Medicine Approaches in Early-Phase CNS Drug Development

Advances in neurobiology, 2023, Vol.30, p.417-455

2023

Volltextzugriff (PDF)

Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor

The Journal of neuroscience, 2011-11, Vol.31 (46), p.16507-16516

2011

Volltextzugriff (PDF)

PROOF OF PRINCIPLE AND BIOMARKER STUDIES SPEED TRANSITION TO POC

Schizophrenia research, 2008, Vol.102 (1), p.43-44

Ereshefsky, Larry

2008

Volltextzugriff (PDF)

Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic

The journal of clinical psychiatry, 1999, Vol.60 Suppl 10, p.20

Ereshefsky, L

1999

Volltextzugriff (PDF)

Mapping of validated apathy scales onto the apathy diagnostic criteria for neurocognitive disorders

Alzheimer's & dementia, 2023-12, Vol.19 (S18), p.n/a

2023

Volltextzugriff (PDF)

Defining and assessing adherence to oral antipsychotics : A review of the literature

Schizophrenia bulletin, 2006-10, Vol.32 (4), p.724-742

2006

Volltextzugriff (PDF)

What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It?

Schizophrenia bulletin, 2010-05, Vol.36 (3), p.504-509

2010

Volltextzugriff (PDF)

CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline

Journal of clinical psychopharmacology, 1999-04, Vol.19 (2), p.155-163

1999

Volltextzugriff (PDF)

Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study

The journal of clinical psychiatry, 2008-10, Vol.69 (10), p.1557-1564

2008

Volltextzugriff (PDF)

S35. THE PLACEBO CONUNDRUM: MITIGATING THE RESPONSE AT THE SITE LEVEL

Schizophrenia bulletin, 2020-05, Vol.46 (Supplement_1), p.S45-S45

2020

Volltextzugriff (PDF)

Effect of Venlafaxine versus Fluoxetine on Metabolism of Dextromethorphan, a CYP2D6 Probe

Journal of clinical pharmacology, 2001-04, Vol.41 (4), p.443-451

2001

Volltextzugriff (PDF)

P4‐357: EFFECTS OF SCOPOLAMINE ON WORKING MEMORY TASK AND RESTING FUNCTIONAL CONNECTIVITY USING FMRI IN HEALTHY KOREAN SUBJECTS

Alzheimer's & dementia, 2014-07, Vol.10 (4S_Part_16)

2014

Volltextzugriff (PDF)

Effects of the glycine reuptake inhibitors bitopertin and RG7118 on glycine in cerebrospinal fluid: results of two proofs of mechanism studies in healthy volunteers

Psychopharmacology, 2016-07, Vol.233 (13), p.2429-2439

2016

Volltextzugriff (PDF)

1 – 25 von 139

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(125)
Mit Volltextzugriff
(75)

Publikationsform

Sprache

Englisch
(139)

Erscheinungsjahr

n.n

Thema

Humans
(69)
Science & Technology
(69)
Life Sciences & Biomedicine
(68)
Psychiatry
(40)
Pharmacology & Pharmacy
(34)
Female
(32)
Male
(32)
Adult
(31)
Biological And Medical Sciences
(27)
Medical Sciences
(27)
Schizophrenia - Drug Therapy
(27)
Pharmacology. Drug Treatments
(23)
Middle Aged
(20)
Neuropharmacology
(20)
Psychology. Psychoanalysis. Psychiatry
(20)
Psychopharmacology
(20)
Drug Interactions
(18)
Neurosciences & Neurology
(14)
Antipsychotic Agents - Therapeutic Use
(13)
Dose-Response Relationship, Drug
(13)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinically Significant Psychotropic Drug-Drug Interactions in the Primary Care Setting

Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disorders

Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease

Relationships Among Subjective and Objective Measures of Adherence to Oral Antipsychotic Medications

Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients

Drug-drug interactions with the use of psychotropic medications. Interview by Diane M. Sloan

Pharmacokinetics and drug interactions: update for new antipsychotics

Diagnostic criteria for apathy in neurocognitive disorders

Quantitative EEG as a translational measure for the assessment of ATH‐1017 neurophysiological changes in mild‐to‐moderate Alzheimer’s disease

AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease

Experimental Medicine Approaches in Early-Phase CNS Drug Development

Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor

PROOF OF PRINCIPLE AND BIOMARKER STUDIES SPEED TRANSITION TO POC

Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic

Mapping of validated apathy scales onto the apathy diagnostic criteria for neurocognitive disorders

The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans

Defining and assessing adherence to oral antipsychotics : A review of the literature

What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It?

CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline

Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study

S35. THE PLACEBO CONUNDRUM: MITIGATING THE RESPONSE AT THE SITE LEVEL

Effect of Venlafaxine versus Fluoxetine on Metabolism of Dextromethorphan, a CYP2D6 Probe

P4‐357: EFFECTS OF SCOPOLAMINE ON WORKING MEMORY TASK AND RESTING FUNCTIONAL CONNECTIVITY USING FMRI IN HEALTHY KOREAN SUBJECTS

Effects of the glycine reuptake inhibitors bitopertin and RG7118 on glycine in cerebrospinal fluid: results of two proofs of mechanism studies in healthy volunteers

Suchergebnisse filtern